… ProQR In-licenses Worldwide Rights to Ophthalmology Drug … said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have … will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through …
… ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten … für die Augenheilkunde von Ionis Pharmaceuticals ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5 … LEIDEN (Niederlande), Oct. 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), ein Unternehmen, das …
… ProQR to Present at 3rd Annual Evercore ISI Virtual … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘ Events ’. The archived webcast will …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR Therapeutics to Host Virtual Analyst and Investor Event … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Program and member of the Scientific Advisory Board at ProQR. Prof. Gideon Hirschfield, MA(Oxon) MB BChir (Cantab) …
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology … & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …